Bio: Dr. Milenko Tanasijevic is the Vice Chair for Clinical Pathology and Quality of the Pathology Department of the Brigham and Women’s Hospital (BWH), the Director of the BWH Clinical Laboratories and an Associate Professor of Pathology at Harvard Medical School. He oversees over forty licensed laboratory sites performing more than 6 MM tests annually. Dr. Tanasijevic’s research as part of the TIMI clinical trial group contributed to the worldwide adoption of cardiac troponins and prompted their inclusion in the redefinition of acute myocardial infarction. He also conducted research in LEAN process improvement and computerized clinical decision support for laboratory service. Dr. Tanasijevic authored more than 75 peer-reviewed publications. He is a co-inventor of 7 issued US patents. Dr. Tanasijevic co-founded Cell Imaging Systems Inc., which invented the technology for building the Bloodhound™ System, the world’s first hematology instrument that integrates digital morphology, cell counting and classification into a single streamlined instrument. ROCHE Diagnostics Inc. acquired the Bloodhound system in July 2013 (http://www.cobas.com/home/product/hematology-testing/cobas-m-511.html. The Roche Cobas 511 system secured CE mark in January 2017 and an FDA approval in March 2018.
Dr. Tanasijevic is the Editor-in-Chief of the Clinics in Laboratory Medicine. He earned his MD at the University Cyril and Methodius in Macedonia and his MBA at the Boston University School of Management.